• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Dorsata Sues Athenahealth, Unified Women’s Healthcare Claiming Deceptive Practices

Share:

July 25, 2023

Dorsata, a maternity-care management platform, has filed a lawsuit against athenahealth and Unified Women’s Healthcare, alleging 11 counts, including theft of trade secrets and breach of contract. Dorsata claims that athenahealth used its trade secrets and cut them out of a deal with Unified after signing a nondisclosure agreement. The lawsuit seeks damages for lost profits and reputational harm. Athenahealth declined to comment on the pending litigation. Dorsata’s platform aims to prevent variations in maternity care using point-of-care technology and clinical data.

Maternity-care management platform Dorsata filed a lawsuit in Suffolk County, Massachusetts, Civil Court yesterday against healthcare technology company athenahealth and nationwide women’s health company Unified Women’s Healthcare, alleging 11 counts against the providers, including theft of trade secrets, unjust enrichment, breach of contract and tortious interference with current customers.

Dorsata offers a tool designed to help prevent variations in medical care during maternity and to decrease the rate of preventable complications by using point-of-care technology and clinical data.

In the complaint, Dorsata, Inc. vs. Athenahealth Group, Inc., searchable here, Dorsata claims that, in 2021, Unified purchased Women’s Health USA, an existing client of Dorsata. After the acquisition, athena approached Dorsata proposing the two entities work together to pursue a broader relationship with Unified by creating an integrated solution to pitch to the company.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

According to Dorsata, after signing a nondisclosure agreement, and amid discussions of athena’s possible acquisition of the EHR player, it provided trade secrets to athena and the two companies made oral agreements to approach Unified as a joint venture.

Dorsata subsequently developed a software product dubbed vU that it and athena would pitch together to Unified.

Dorsata alleges that athena, meanwhile, was creating its own version of vU to pitch to Unified, without Dorsata’s knowledge. It simultaneously convinced the EHR player to sign a promissory note with an exclusivity clause, meaning Dorsata was prevented from conducting business with athena competitors.

Dorsata had needed a cash infusion for its business, and athena provided $6 million to the company, the terms of which were addressed in the promissory note.

Dorsata says Unified aided and abetted athena’s actions, and the two companies cut Dorsata out of the deal, resulting in, among other incurrences, difficulty for Dorsata to pay back its $6 million due to athena by 2025.

Dorsata also alleges athena is eliciting input from the company’s existing customers, requesting that companies compare its uV-type product to Dorsata’s and that athena is gaining feedback about how to enhance its offering.

Dorsata brought nine causes of action against athena, including unfair and deceptive acts and practices, breach of oral contract, breach of fiduciary duty, common law fraud, unjust enrichment, theft of trade secrets, tortious interference with current customers, breach of nondisclosure agreement and commercial disparagement.

The company brought two counts against Unified, including aiding and abetting a breach of fiduciary duty and breach of contract.

Dorsata is seeking damages incurred from a loss of expected profits, the value of injury to reputation, a loss of company valuation, the value of future lost business and damages for unlawfully gained commercial marketplace advantage.

It is also requesting the court find the promissory note was “a fraudulent artifice intended to prevent Dorsata from competing in the marketplace” and, therefore, prevent athena from seeking to collect the $6 million.

“We’ve been severely damaged, and we hope the court will rectify the situation,” David Fairbrothers, cofounder and CEO of Dorsata, told MobiHealthNews in an email.

In an email to MobiHealthNews, athenahealth said it doesn’t comment on pending litigation.

Source: MobihealthNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Starboard drops out of Celgene fight as proxy firms back Bristol bidStarboard drops out of Celgene fight as proxy firms back Bristol bid
  • Oncology Nutrition Market Growth Factors and Application By Regions Analysis & Forecast By 2027Oncology Nutrition Market Growth Factors and Application By Regions Analysis & Forecast By 2027
  • Building the Foundations of Digital Health LiteracyBuilding the Foundations of Digital Health Literacy
  • Harrison Street Acquires Osborn Triangle, a State-of-the-Art Office and Laboratory Complex Located in Cambridge, Mass.Harrison Street Acquires Osborn Triangle, a State-of-the-Art Office and Laboratory Complex Located in Cambridge, Mass.
  • Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron BiotechnologyArcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology
  • Internet Brands’ WebMD Acquires Frontline Medical CommunicationsInternet Brands’ WebMD Acquires Frontline Medical Communications
  • Three-Company M&A Deal Creates New Clinical Trial Industry Leader, Apex Innovative Sciences, Inc.Three-Company M&A Deal Creates New Clinical Trial Industry Leader, Apex Innovative Sciences, Inc.
  • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product PortfolioSupernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications